The adherence in the treatment of chronic hepatitis C;Adherencja w leczeniu przewlekłego zapalenia wa̧troby typu C

Polski Merkuriusz Lekarski

Volumn 18, Issue 106, 2005, Pages 469-472

  Pawłowska, Małgorzata ^a,b   Halota, Waldemar ^a  

^a Katedra I Klinika Chorób Zaka nych I Hepatologii Cellegium Medicum UMK   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Adherence; Chronic hepatitis C; Side effects

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ALOPECIA; ANEMIA; ANOREXIA; ANXIETY; ATTENTION DEFICIT DISORDER; CACHEXIA; DEPRESSION; DIARRHEA; DYSPHORIA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; LEUKOPENIA; NAUSEA AND VOMITING; OSTEOARTHRITIS; PATIENT COMPLIANCE; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SUICIDAL BEHAVIOR; THROMBOCYTOPENIA; THYROID DISEASE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; QUALITY OF LIFE; RIBAVIRIN; TREATMENT OUTCOME;

EID: 18444396868     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Barclay L.: Obesity predicts poor response to hepatitis C treatment. Hepatology, 2003, 38, 639-644.
2. Bernstein D., Kleinman L., Barker C.M. i wsp.: Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology, 2002, 35, 704-708.
3. Davis G.L.: Assesing health-related quality of life in chronic hepatitis C using the sickness impact profile. Clin. Ther., 1994, 16, 334-343.
4. Davis G.L., Wong J.B., McHutchinson J. i wsp.: Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 2003, 38, 645-652.
5. Kwo P.Y.: Management of side effects of interferon and ribavirin therapy for chronic HCV infection. Psychological aspects of hepatitis C. Hepatology Associates Course, AASLD 2002.
6. Lindsay K.L., Trepo C., Heintges T. i wsp.: A randomised, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology, 2001, 34, 395-403.
7. Luken K.K.: Adherence in the management of HCV therapy. Hepatology Associates Course, AASLD 2002.
8. Manns M.P., McHutchinson J.G., Gordon S.C. i wsp.: Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet, 2001, 358, 958-65.
9. McHutchinson J.G., Patel K.: Approach to treatment of chronic hepatitis C. in M.Buti and R.Esteban "Viral hepatitis" Barcelona 2003, 153-161.
10. McHutchinson J.G., Gordon S.C., Schiff E.R. i wsp.: Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med., 1998, 339, 1485-1492.
11. McHutchinson J.G., Manns M.P., Patel K. i wsp.: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology, 2002, 123, 1061-1069.
12. Pawłowska M., Halota W.: Postȩp w leczeniu wzw C - interferon pegylowany. Przegl. Epid., 2001, 55, Supl.3, 169-173.
13. Pawłowska M.: Epidemiologiczno-kliniczna analiza chorych na przewlekłe zapalenie wa̧troby typu C ze szczególnym uwzglȩdnieniem wyników różnych metod leczenia oraz jego uwarunkowaṅ immunologicznych. Rozprawa habilitacyjna 2003.
14. Pessione F., Degos F., Marcellin P. i wsp.: Hepatology, 1998, 27(6), 1717-1722.
15. Poynard T.: Viral hepatitis C. Lancet, 2003, 362, 2095-2100.
16. Poynard T., Marcellin P., Lee S.S. i wsp.: Randomized trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet, 1998, 352, 1426-1432.